Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Научно-методический центр по изучению болезни Альцгеймера НЦПЗ РАМН, Москва
Список исп. литературыСкрыть список 1. Букатина Е.Е. Соц. и клин. психиатр. 1997; 7 (3): 136–15. 2. Гаврилова С.И. Руководство по психиатрии: В 2-х т. Т.2/А.С.Тиганов, А.В.Снежневский, Д.Д.Орловская и др.; Под ред. А.С.Тиганова. М.: Медицина, 1999; 57–117. 3. Гаврилова С.И. В кн.: Болезнь Альцгеймера и старение: от нейробиологии к терапии. Под редакцией Гавриловой С.И. М., 1999; 25–32. 4. Гаврилова С.И., Жариков Г.А. Вестн. РАМН, 2001; 7: 13–8. 5. Жариков Г.А., Рощина И.Ф. Психиатр. и психофармакотер. 2001; 2 (приложение): 3–6. 6. Колыхалов И.В., Селезнева Н.Д., Калын Я.Б. и др. В кн.: Болезнь Альцгеймера и старение: от нейробиологии к терапии. Под редакцией Гавриловой С.И. М., 1999; 90–7. 7. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, D.C. 1994. 8. Anand R. Clinical expert report: Exelon/Alzheimer's disease. Basle, Switzerland: Novartis Pharma AG, 1997. (Data on file). 9. Anand R, Gharabawi G, Enz A. J Drug Dev Clin Pract 1996; 8: 109–16. 10. Arendt T, Bruckner MK, Lange M. et al. Neurochem Int 1992; 21: 381–96. 11. Auriacombe S, Pere J-J, Loria-Kanza Y, Vellas B. Current Med Res Opinion 2002; 18 (3): 129–38. 12. Ballard CG. Eur Neurol 2002; 47: 64–70. 13. Bartus RT, Dean RL, Beer B, Lippa AS. Science 1982; 217: 408–17. 14. Bullock R, Moulias R, Steinwachs K-C, Cicin-Sain AG, Spiegel R. Int Psychogeriatrics 2001; 13 (suppl. 2): Abstract P.248. 15. Corey-Bloom J, Anand R, Vcach J. for the ENA-713 B352 Study Group. Int J Geriatr Psychopharmacol 1998; 1: 55–65. 16. Costa J, Anand R, Cutler N. et al. Proc Am Psych Assoc 1999; Abstract 561. 17. Coyle J, Price D, Delong M. Science 1983; 219: 1184–90. 18. Culter NR, Polinsky RJ, Sramek JJ. et al. Acta Neurol Scand 1998; 97: 244–50. 19. Cummings J, Anand R, Koumaras В. et al. Neurology 2000; 54: A468. 20. Cummings J, Anand R, Koumaras B, Hartman B. Behavioral benefits in Alzheimer's disease patients residing in a nursing home following 52 weeks of treatment with rivastigmine. Poster presented at the АРА, New Orleans, 2001. 21. Davies P. Brain Res 1979; 171: 319–27. 22. Davies P, Maloney AJF. Lancet 1976; 2: 1403–4. 23. Doraiswamy PM. Primary Psychiatry 1996; 3 (11): 3–11. 24. Doraiswamy M, Anand R, Hartman R. et al. Prog Neuropsychopharmacol Biol Psychiatry 2002; In press. 25. Ernst RL, Hay JW. Am J Public Health 1994; 84: 1261–4. 26. Ernst RL, Hay JW. Alzheimer Dis Assoc Disord 1997; 11 (suppl. 6): 135–45. 27. Etemad B. Int Psychogeriatr 2001; 13 (suppl. 2): 241 (Abstract P246). 28. Farlow M, Anand R. Patterns of cholineslcrase inhibition in normal controls and Alzheimer's disease patients: Correlation of cognitive improvement with the type of esterase inhibition. Poster presented at the Sixth Internal ional Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, April 2000. 29. Farlow M, Anand R, Messina JJr. et al. Eur Neurol 2000; 44: 234–41. 30. Fraser M, Snyder EH. Clinical Geriatrics 2000; 8 (2): 1–11. 31. Freo U, Carbonin C, On C, Pizzolato G. Exelon data file. Bibliography 2000–2002; Abstract 677.5. 32. Geula C, Mesulam MM. In Bick KL, Katzman R, Terry RD, eds. Alzheimer Disease. Raven Press Ltd, New York 1994; 263–91. 33. Giacobini E. Cholinesterase inhibitors for Alzheimer’s disease therapy: pharmacokinetic and pharmacodynamic considerations//Pgarmacotherapy of Alzheimer’s Disease. Ed. Gauthier S. Montreal: Martin Dunitz, 1995; 75–92. 34. Giacobini E. Jpn J Pharmacol 1997; 74: 225–41. 35. Giacobini E. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy; in Giacobini E (ed): Cholinesterases and Cholinesterase inhibitors. London, Martin Dunitz. 2000; 181–226. 36. Gottfries CG, Blennow K, Karlsson I, Wallin A. Dementia 1994; 5: 163–7. 37. Grossberg G, Irwin P, Spiegel R. et al. Rivastigmine in Alzheimer's disease: efficacy over two years compared with historical controls. Poster presented at 10th Congress of the International Psychogcriatric Association (IPA), Nice, France, 9–14 September, 2001. 38. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV. et al. Pharmacoeconomics 2000; 17 (4): 351–60. 39. Kalaria RN. Neurobiol Aging 2000; 57: 1295–300. 40. Kumar V, Anand R, Messina J. et al. Eur J Neurol 2000; 7: 159–69. 41. Kumar V, Kalache E. Int J Clin Pharmacol Ther Toxicol 1991; 29 (1): 356–7. 42. Lamb HM, Goa KL. Pharmacoeconomics 2001; 19 (3): 303–18. 43. Liesiene V. Practical diagnosis of mild cognitive impairment./in the book Neurodegenerative diseases: the challenge for the future. Program and Notebook. Praha Symposium, October 18, 2002; 22. 44. McGeer P, McGeer E, Suzuki J. et al. Neurology 1984; 34: 741. 45. McKeith I, Del Ser T, Spano F. et al. Lancet 2000; 356: 2031–6. 46. McKhann G, Drachman D, Folstein М. et al. Neurology 1984; 146: 939–44. 47. Mesulam M, Geula C. Ann Neurol 1994; 36: 722–7. 48. Moretti R, Torre P, Antonello RM, Cazzato G. Eur J Nerol 2001; 8: 361–2. 49. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine is safe and effective for at least 22 months in patients with subcortical vascular dementia. Second International Congress on Vascular Dementia, Salzburg, Austria, January 25, 2002; Abstract No. 37. 50. O'Brien JT, Paling S, Barber R. et al. Neurology 2001; 56: 1386–8. 51. Реnу EK, Реnу RH, Blessed G, Tomlinson BE. Neuropathol Appl Neurobiol 1978; 4: 273–7. 52. Polinsky RJ. Clin Ther 1998; 20 (4): 634–47. 53. Potkin SG, Anand R, Hartman R, Veach J. Prog Neuropsychopharmacol Biol Psychiatry 2002; In press. 54. Rice DP. et al. Health Aff (Millwood) 1993; 12: 164–76. 55. Rцsler M, Anand R, Cicin-Sain A. et al. BMJ 1999; 318: 633–8. 56. Schneider LS, Anand R, Farlow MR. Int J Geriatr Psychophannacol 1998; L (suppl. 1): S.26–S34. 57. Shea C, McKnight C, Rockwood K. Int Psychogeriatr 1998; 10: 229–38. 58. Shaw WS. et al. Ann Behav Med 1997; 19: 101–9. 59. Souкtre EJ. et al. Int Psychogeriatr 1995; 7: 115–22. 60. Spencer CM, Noble S. Drugs & Aging 1998; 5: 391–411. 61. Taylor P, Radic Z. Ann Rev Phannacol Toxicol 1994; 34: 281–20. 62. Weinstock M. CNS Drugs 1999; 12: 307–23. 63. Wilson AL, Langley LK, Monley J. et al. Pharmacol Biochem Behav 1995; 51 (2–3): 509–14. 64. Xie W, Stribley JA, Chatonnet A. et al. J Pharmacol Exp Ther 2000; 293: 896–902. 65. Zurad EG. Drug Benefit Trends 2001; 13: 27–40.